ArticleFamilial cancer2007
Improved survival in BRCA2 carriers with ovarian cancer.
Article in Familial cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 5 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.Medicine · 2018Pooled it
- Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.Oncotarget · 2017Pooled it
- Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.British journal of cancer · 2015Pooled it
- Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Pooled it
- Pooled it
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.British journal of cancer · 2013Trial
- BRCA Status Dictates Wnt Responsiveness in Epithelial Ovarian Cancer.Cancer research communications · 2024Article
- Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives.Frontiers in oncology · 2021Review
- Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.CA: a cancer journal for clinicians · 2019Review
- Novel BRCA1 splice-site mutation in ovarian cancer patients of Slavic origin.Familial cancer · 2018Article
- The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.Cancer · 2017Review
- Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.OncoTargets and therapy · 2017Review
- Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.Familial cancer · 2016Article
- Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.Ecancermedicalscience · 2016Article
- Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.Hereditary cancer in clinical practice · 2016Article
- Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: a pilot study.International journal of biochemistry and molecular biology · 2014Article
- Translational genomics in cancer research: converting profiles into personalized cancer medicine.Cancer biology & medicine · 2013Review
- Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.Journal of the National Cancer Institute · 2013Article
- Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Pharmacogenomics · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesThe objective of this study was to investigate survival of ovarian cancer patients with BRCA1 and BRCA2 mutations compared to those without mutations in a population-based sample of incident epithelial ovarian cancer cases.
methodsFollow-up for vital status was performed on a population-based sample of 232 women with incident epithelial ovarian cancer recruited between December 13, 2000 and September 30, 2003 in the Tampa Bay area. Survival analysis using Cox regression was performed on (1) all 232 cases and (2) the 209 invasive epithelial ovarian cancer cases. Results of the two analyses were similar, thus data involving the 209 invasive epithelial cancer cases are presented, as this was judged to be more clinically relevant.
resultsIn the multivariate analysis, BRCA status and stage were statistically significant, and were adjusted for in the survival analysis model. The Kaplan-Meier method estimated expected survival at 4 years of 83% of BRCA2 carriers compared to 37% of BRCA1 carriers and 12% of non-carriers. There was a statistically significant difference between BRCA2 carriers and non-carriers (p = 0.013). No statistically significant survival differences were seen for BRCA1 carriers when compared with either BRCA2 carriers or non-carriers.
conclusionThese data suggest that BRCA2 mutation carriers with ovarian cancer may have better survival than BRCA1 carriers and non-carriers. The etiology of this possible survival advantage is currently unknown. Larger studies are needed to confirm these results and to clarify their etiology and clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.